Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 28, 2017 ) ReportsWeb.com has announced the addition of the “Burkholderia Infections - Pipeline Review, H2 2016” The report outlines the evolution of enterprise content management, and identifies and assesses the best performing vendors in the market. Summary Pharmaceutical and Healthcare latest pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Burkholderia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Burkholderia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. For more information about this report at http://www.reportsweb.com/burkholderia-infections-pipeline-review-h2-2016 Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Burkholderia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Burkholderia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Burkholderia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Burkholderia Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Burkholderia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530747/sample
Few Points from Table of Content: List of Tables 5 List of Figures 6 Introduction 7 Publisher Report Coverage 7 Burkholderia Infections Overview 8 Therapeutics Development 9 Pipeline Products for Burkholderia Infections - Overview 9 Pipeline Products for Burkholderia Infections - Comparative Analysis 10 Burkholderia Infections - Therapeutics under Development by Companies 11 Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes 12 Burkholderia Infections - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Burkholderia Infections - Products under Development by Companies 16 Burkholderia Infections - Products under Investigation by Universities/Institutes 17 Burkholderia Infections - Companies Involved in Therapeutics Development 18 Aridis Pharmaceuticals LLC 18 Arno Therapeutics Inc 19 Bavarian Nordic A/S 20 Emergent BioSolutions Inc 21 Eumedica SA 22 Grifols SA 23 Sarepta Therapeutics Inc 24 Soligenix Inc 25 Syntiron LLC 26 Purchase Complete Report at http://www.reportsweb.com/buy&RW0001530747/buy/2000 Call: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|